Editorial Commentary
Incremental innovation in endoscopic ultrasound-guided biopsy: does the tip make the difference?
Annals of Pancreatic Cancer
2026;
9:
25
.
(30 August 2026)
Editorial Commentary
Engineered exosomes silence oncogenic KRASG12D and awaken immunity in pancreatic cancer
Annals of Pancreatic Cancer
2026;
9:
24
.
(30 August 2026)
Editorial Commentary
Remodeling of tumour microenvironment of pancreatic cancer: can agonistic anti-CD40 antibodies give a new direction?
Annals of Pancreatic Cancer
2026;
9:
23
.
(30 August 2026)
Editorial Commentary
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: interpreting the AGICC study
Annals of Pancreatic Cancer
2026;
9:
22
.
(30 August 2026)
Editorial Commentary
Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies
Annals of Pancreatic Cancer
2026;
9:
21
.
(30 August 2026)
Editorial Commentary
18F-prostate specific membrane antigen positron emission tomography/computed tomography for pancreatic ductal adenocarcinoma: not specific enough
Annals of Pancreatic Cancer
2026;
9:
20
.
(30 August 2026)
Editorial Commentary
Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance
Annals of Pancreatic Cancer
2026;
9:
19
.
(30 August 2026)
Case Report
Double primary biliary malignancy: synchronous gallbladder carcinoma and extrahepatic cholangiocarcinoma in a Whipple specimen—a case report and literature review
Annals of Pancreatic Cancer
2026;
9:
18
.
(30 August 2026)
Case Report
ATP1B1::PRKACA fusion-defined intraductal oncocytic papillary neoplasm of the pancreas: a case report
Annals of Pancreatic Cancer
2026;
9:
17
.
(30 August 2026)
Review Article
Liquid biopsy and biomarkers in pancreatic ductal adenocarcinoma: from concept to clinical translation—a narrative review
Annals of Pancreatic Cancer
2026;
9:
16
.
(30 May 2026)
Editorial Commentary
Can preoperative radiotherapy reduce the risk of postoperative pancreatic fistula after pancreatoduodenectomy?
Annals of Pancreatic Cancer
2026;
9:
15
.
(30 May 2026)
Editorial Commentary
Comparing neoadjuvant regimens in resectable and borderline resectable pancreatic cancer: lessons from PREOPANC-2
Annals of Pancreatic Cancer
2026;
9:
14
.
(30 May 2026)
Editorial Commentary
CDK4/6 inhibition in pancreatic cancer: lessons learned as the therapeutic landscape evolves
Annals of Pancreatic Cancer
2026;
9:
13
.
(30 May 2026)
Editorial Commentary
Cluster of differentiation 40 agonism as a priming strategy in pancreatic ductal adenocarcinoma: biomarker insights from OPTIMIZE-1
Annals of Pancreatic Cancer
2026;
9:
12
.
(30 May 2026)
Editorial Commentary
PASS-01: the final step on the journey towards the optimal chemotherapy regimen for metastatic pancreatic adenocarcinoma?
Annals of Pancreatic Cancer
2026;
9:
11
.
(30 May 2026)
Editorial Commentary
Perioperative therapy to control hepatic micrometastases in pancreatic ductal adenocarcinoma: an appraisal of the TOSPAC-02 study
Annals of Pancreatic Cancer
2026;
9:
10
.
(30 May 2026)
Editorial Commentary
The evolving neoadjuvant landscape in pancreatic cancer: biology often overrides anatomy in achieving margin-negative resection
Annals of Pancreatic Cancer
2026;
9:
9
.
(30 May 2026)
Editorial Commentary
Stereotactic body radiotherapy in pancreatic ductal adenocarcinoma: interpreting the results of the SPAN-C trial
Annals of Pancreatic Cancer
2026;
9:
8
.
(30 May 2026)
Letter to the Editor
Real-world outcomes of chemotherapy in pancreatic cancer: considerations for validity and interpretation
Annals of Pancreatic Cancer
2026;
9:
7
.
(30 January 2026)
Letter to the Editor
Improving long-term outcomes in resectable pancreatic cancer
Annals of Pancreatic Cancer
2026;
9:
6
.
(30 January 2026)
Original Article
Estimation of symptoms burden in advanced pancreatic cancer patient and impact of palliative care intervention on it
Annals of Pancreatic Cancer
2026;
9:
5
.
(30 January 2026)
Editorial Commentary
Optimal management of resectable pancreatic ductal adenocarcinoma
Annals of Pancreatic Cancer
2026;
9:
4
.
(30 January 2026)
Letter to the Editor
FOLFIRINOX for pancreatic cancer: a real-world registry analysis
Annals of Pancreatic Cancer
2026;
9:
3
.
(30 January 2026)
Editorial Commentary
Defining risk-adapted adjuvant therapy in resectable pancreatic cancer: an editorial commentary on long-term outcomes from ESPAC4
Annals of Pancreatic Cancer
2026;
9:
2
.
(30 January 2026)
Editorial Commentary
ESPAC-4 long-term follow-up: shall we choose gemcitabine and capecitabine as adjuvant therapy for elderly and low-risk pancreatic adenocarcinoma following surgical resection?
Annals of Pancreatic Cancer
2026;
9:
1
.
(30 January 2026)